20304-86-3

Basic information

• Product Name: 5-METHYLBENZOFURAZAN
• Synonyms: 5-METHYLBENZOFURAZAN;5-METHYL-2,1,3-BENZOXADIAZOLE;BUTTPARK 29\04-28;5-METHYLBENZOFURAZAN 97%;5-Methylbenzfurazan;5-Methyl-2,1,3-benzoxadizole
• CAS NO: 20304-86-3
• Molecular Formula: C₇H₆N₂O
• Molecular Weight: 134.14
• Mol File: 20304-86-3.mol
• Article Data: 10

Chemical Properties

• Melting Point: 33-35°C
• Boiling Point: 209.2°C at 760 mmHg
• Flash Point: 82°C
• Appearance: /
• Density: 1.229g/cm³
• Vapor Pressure: 0.297mmHg at 25°C
• Refractive Index: 1.601
• CAS DataBase Reference: 5-METHYLBENZOFURAZAN(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHYLBENZOFURAZAN(20304-86-3)
• EPA Substance Registry System: 5-METHYLBENZOFURAZAN(20304-86-3)

Safety Data

• Hazard Codes: Xi
• Safety Statements: S24/25:Avoid contact with skin and eyes.
• Hazardous Substances Data: 20304-86-3(Hazardous Substances Data)

Usage

General Description

5-Methylbenzofurazan is a chemical compound with the formula C9H8N2. It is characterized by a fusible and dark solid with a mild odor. The chemical is insoluble in water but soluble in alcohol, acetone, and ether. It is used widely in the field of chemistry for its oxidative properties. In the presence of moisture, 5-Methylbenzofurazan can cause skin and eye burns. It should be handled with care, using protective clothing and eye protection.

InChI:InChI=1/C7H6N2O/c1-5-2-3-6-7(4-5)9-10-8-6/h2-4H,1H3

Upstream product

• 612-45-3 4-methyl-2-nitroacetanilide 
• 19164-41-1 5-methylbenzofuroxan 
• 98549-95-2 4-methyl-1,2-dinitroso-benzene 
• 40468-66-4 (4-methyl-2-nitro-phenyl)-(1,2,5-triphenyl-1H-1λ⁵-phosphol-1-ylidene)-amine 
• 2617-79-0 N-(4-chlorophenyl)formamide 
• 90824-02-5 C₇H₅ClNO^(1-)*K⁽¹⁺⁾ 
• 53178-71-5 4-methylcyclohexa-3,5-diene-1,2-dione dioxime 
• 20615-75-2 4-azido-3-nitro-toluene 
• 54948-54-8 5-methyl-2-nitroazidobenzene 
• 89-62-3 4-methyl-2-nitroaniline 
• 1073355-14-2 5?(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[c][1,2,5]oxadiazole 
• 74-88-4 methyl iodide 
• 3524-05-8 6-methylbenzofuroxan 

Downstream Products

• 32863-31-3 5-(bromomethyl)benzofurazan 
• 16322-21-7 5-Methyl-4-nitro-benzofurazan 
• 54286-59-8 5-Methylbenzofurazan-4-carbonitril 
• 32863-33-5 5-formylbenzofurazan 
• 6344-72-5 6-methylquinoxaline 
• 1297593-67-9 C₁₇H₁₄N₂O₃ 
• 480441-88-1 2-benzenesulfonyl-3,6-dimethyl-quinoxaline 1,4-dioxide 
• 480441-68-7 3,6-dimethyl-2-phenylsulfanyl-quinoxaline 1,4-dioxide 

Relevant articles and documents

A Common, Facile and Eco-Friendly Method for the Reduction of Nitroarenes, Selective Reduction of Poly-Nitroarenes and Deoxygenation of N-Oxide Containing Heteroarenes Using Elemental Sulfur

A transition metal-free, environment-friendly and practical protocol was developed either for the reduction of nitroarenes or for the deoxygenation of N-oxide containing heteroarenes. The reaction proceeded with the use of a non-toxic and cheap feedstock as elemental sulfur in aqueous methanol under relatively mild conditions. Green chemistry credentials were widely favorable compared to traditional and industrial protocols with good E-factors and a low production of waste. The strategy allowed the efficient reduction of a large variety of substituted-nitroarenes including various o-nitroanilines as well as selective reduction of various poly-nitroarenes in excellent yields with a broad substrate scope. The protocol was successfully extended to the deoxygenation of some N-oxide containing heteroarenes, like benzofuroxans, phenazine N,N'-dioxides, pyridine N-oxides, 2H-indazole N1-oxides, quinoxaline N1,N4-dioxides and benzo[d]imidazole N1,N3-dioxides. A gram-scale example for the synthesis of luminol, in green conditions, was reported. A solid mechanism of reaction was proposed from experimental evidences.

SELECTIVE MELANIN CONCENTRATING HORMONE-1 (MCH1) RECEPTOR ANTAGONISTS AND USES THEREOF

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. This invention further provides a method of treating a feeding disorder in a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. In an embodiment of the invention, the feeding disorder is bulimia, bulimia nervosa or obesity.

New analogs of nitrobenzylthioinosine

This invention relates to new analogs or derivatives of nitrobenzylthioinosine, use of these new analogs of nitrobenzylthioinosine for the treatment of pain and various other diseases as well as pharmaceuticals comprising at least on new analog of nitrobenzylthioinosine.